The below is a snippet from a very-cogent recent letter of response to Dr. Davidson's Vytorin analysis, as earlier-published by the Cleveland Clinic Journal of Medicine -- on what we really do -- and don't -- know about Vytorin/Zetia and the efficacy of various cholesterol-lowering mechanisms of action:
. . . .The point is that we need more data. Until we have that outcomes data we should not be saying a drug is safe as a matter of fact. Physicians need to learn the lessons we should have learned from drugs such as torcetrapib or erythropoietin and so many others. We often think we are doing a good thing by correcting lab values, but we often learn too late that we harmed the patient at a staggering ethical and financial cost. . . .
Wow. Do go read it all, over there. This, with a sincere hat tip to Marilyn Mann, an occasional guest blogger at Gooznews. If you click that link, in her name, you'll see another development has taken place on the "Silly Rabbit, Vytorin is NOT for Kids" story (see my goofy graphic, at lower-left) -- hers updates the European-end of the story, which she originally-authored over at Gooznews. Cheers!
No comments:
Post a Comment